Group/Parameter | Urticaria (n = 64) | Control group (n = 40) | ||
---|---|---|---|---|
IL-6 (pg/ml) | AU (n = 32) | 13.27 (10.25–15.5)* | 7.42 (6.21–8.45) | |
CU (n = 32) | 13.91 (11.32–15.71)* | |||
Mild CU (n = 14) | 13.82 (11.4–14.53) * | |||
Moderate CU (n = 8) | 12.72 (11.09–14.43) * | |||
Severe CU (n = 10) | 15.71 (11.35–17.82) * | |||
IL-17A (pg/ml) | AU (n = 32) | 41.5 (38.35–44.15) * | 27.13 (20.37–36.45) | |
CU (n = 32) | 41.4 (38.55–48.25) * | |||
Mild CU (n = 14) | 42.95 (39.6–47.6) * | |||
Moderate CU (n = 8) | 40.5 (34.3–45.55) * | |||
Severe CU (n = 10) | 41.45 (38.4–50.2) * | |||
IL-18 (pg/ml) | AU (n = 32) | 114.2 (100.45–125.5) * | 133.25 (122.95–142.15) | |
CU (n = 32) | 115.8 (102.5–129.5) * | |||
Mild CU (n = 14) | 115.05 (101.5–130.1) * | |||
Moderate CU (n = 8) | 111.9 (101.9–123.35)* | |||
Severe CU (n = 10) | 123.2 (104.7–132.1)* | |||
IL-23 (pg/ml) | AU (n = 32) | 376.5 (308–434.5) * | 603.0 (527.5–674.0) | |
CU (n = 32) | 361.5 (289.0–462.0) * | |||
Mild CU (n = 14) | 307.0 (289.0–364.0) * | |||
Moderate CU (n = 8) | 459.0 (411.0–506.5) * | |||
Severe CU (n = 10) | 365.0 (275.0–463.0) * | |||
RANTES (pg/ml) | AU (n = 32) | 3791.0 (2896.5–4516.5) * | 5822.0 (5337.5–6261) | |
CU (n = 32) | 3735.5 (3372.5–4676.5) * | |||
Mild CU (n = 14) | 4190.0 (3381.0–5127.0) */ ** | |||
Moderate CU (n = 8) | 3140.0 (2806.5–3596.0) */*** | |||
Severe CU (n = 10) | 3871.5 (3725.0–4271.0) * | |||
IP-10 (pg/ml) | AU (n = 32) | 48.25 (41.95–51.2) * | 73.25 (65.85–85.6) | |
CU (n = 32) | 48.0 (39.95–50.35) * | |||
Mild CU (n = 14) | 49.3 (43.2–50.6) * | |||
Moderate CU (n = 8) | 45.3 (38.1–49.15) * | |||
Severe CU (n = 10) | 47.45 (39.7–50.2) * |